Literature DB >> 3141209

Cytotoxic immunosuppressive drug treatment strategy in pure red cell aplasia.

F C Firkin1, D Maher.   

Abstract

Remissions occurred in 2 of 5 consecutive cases of acquired pure red cell aplasia (PRCA) during an initial course of treatment with either azathioprine and prednisolone, or cyclophosphamide and prednisolone. Crossover to therapy with the alternative cytotoxic immunosuppressive agent in conjunction with continued administration of prednisolone in 3 unresponsive cases resulted in remission induction. Crossover to azathioprine was effective in 2 cases initially unresponsive to cyclophosphamide, and crossover to cyclophosphamide in 1 initially unresponsive to azathioprine. This emphasises that lack of cross-resistance to these drugs can occur in PRCA, and that crossover to treatment with the alternative agent in refractory cases is a useful strategy which has been underutilised in reported approaches to management. Administration of the effective regimen was continued for a mean of 15 months, and this more extended period of treatment was associated with a longer mean duration of remission than reported in previous studies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3141209     DOI: 10.1111/j.1600-0609.1988.tb01183.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  3 in total

1.  Pure red cell aplasia with follicular lymphoma showing regression and progression parallel to lymphoma.

Authors:  Go Yamamoto; Hiroaki Maki; Motoshi Ichikawa; Mineo Kurokawa
Journal:  Int J Hematol       Date:  2011-11-26       Impact factor: 2.490

Review 2.  Pure red cell aplasia: review of treatment and proposal for a treatment strategy.

Authors:  A Raghavachar
Journal:  Blut       Date:  1990 Aug-Sep

Review 3.  Acquired pure red cell aplasia: updated review of treatment.

Authors:  Kenichi Sawada; Naohito Fujishima; Makoto Hirokawa
Journal:  Br J Haematol       Date:  2008-05-28       Impact factor: 6.998

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.